Cipla, the 89-year-old desi pharma darling, is flexing with ₹1.26 lakh crore market cap, debt barely worth a Bangalore startup loan (₹438 Cr), and 7,500 sales reps convincing doctors faster than LIC agents at Diwali. They claim respiratory dominance (22% market share) and global generics hustle, but the stock has moved slower than a government file in the last 1 year (-4.7%).
2. Introduction
Cipla’s life story is like a Bollywood multi-starrer: born in 1935, grew under Dr. K.A. Hamied’s socialist dream of “medicine for all,” and today, it’s the third-largest in India’s domestic Rx market. From asthma inhalers to generic Viagra knockoffs, Cipla has been everyone’s chemist uncle.
But here’s the spicy twist: while sales growth has been pedestrian (10% CAGR over 5 years), profits have been hitting the gym (29% CAGR). Basically, Cipla is that middle-class cousin who doesn’t get taller but keeps bulking in the gym.
Yet the market keeps asking — will Cipla ever dethrone Sun Pharma, or will it remain the eternal 2nd runner-up in this Miss Pharma pageant?
3. Business Model – WTF Do They Even Do?
Cipla makes and sells everything from paracetamol to high-end antivirals across 65 therapeutic categories and 1,500+ products. Their portfolio looks like D-Mart aisles: respiratory (37% revenue), anti-infectives (16%), cardiac (12%), antivirals (5%), and a masala mix of pain, derma, CNS, and GI.
They also run an API business that churns out 200+ generics across 62 countries, making them the pharmaceutical version of Ramesh & Suresh from 5-Star ads: always exporting but rarely starring.
And don’t forget the consumer brands — Nicotex, Omnigel, Cofsils — India’s middle-class medicine cabinet staples. If you haven’t used at least one Cipla product, you either live in Antarctica or are too loyal to Dabur Chyawanprash.
4. Financials Overview
Quarterly Snapshot (₹ Cr):
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
6,957
6,694
6,730
3.9%
3.4%
EBITDA
1,778
1,716
1,538
3.6%
15.6%
PAT
1,292
1,175
1,214
10.0%
6.4%
EPS (₹)
16.1
14.6
15.1
10.3%
6.3%
Commentary: Steady growth, but nothing to make SEBI jump out of its chair. PAT is growing faster than revenue, which means cost control is tighter than mom’s Diwali budget. EPS annualised at ~₹64 — which gives us a P/E of ~24. Not cheap, not crazy.
5. Valuation – Fair Value Range Only
P/E Method: Industry P/E: 33, Cipla’s EPS (TTM): 66.8. Fair Range = 20× to 28× = ₹1,336 – ₹1,870.
EV/EBITDA Method: Cipla EV: ₹1.26 lakh Cr, EBITDA TTM: ~₹8,170 Cr. Current EV/EBITDA = 15.5×. Peer median ~18×. Fair Range = 14×–18× → EV = ₹1.14 – ₹1.47 lakh Cr. Per share: ₹1,360 – ₹1,760.
DCF (conservative 10% growth, 11% WACC): Fair value range = ₹1,400 – ₹1,750.
Range Consensus: ₹1,350 – ₹1,800. ⚠️ Disclaimer: This fair value range is for educational purposes only and not investment advice.
6. What’s Cooking – News, Triggers, Drama
USFDA inspections: Bommasandra got a “VAI” (Voluntary Action Indicated). Translation: not a red flag, more like teacher’s remark “can do better.”
Acquisitions: 20% stake in iCaltech (diagnostics) and renewable energy tie-ups with AMP Energy. Because why cure just asthma when you can cure climate change too?
Partnerships: Sanofi CNS portfolio distribution deal. Basically, Cipla will sell Sanofi’s depression pills while Sun Pharma depresses Cipla’s investors.
